HRP20151143T1 - Novi antimalarijski agensi - Google Patents
Novi antimalarijski agensi Download PDFInfo
- Publication number
- HRP20151143T1 HRP20151143T1 HRP20151143TT HRP20151143T HRP20151143T1 HR P20151143 T1 HRP20151143 T1 HR P20151143T1 HR P20151143T T HRP20151143T T HR P20151143TT HR P20151143 T HRP20151143 T HR P20151143T HR P20151143 T1 HRP20151143 T1 HR P20151143T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridin
- phenyl
- amine
- methylsulfonyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29582110P | 2010-01-18 | 2010-01-18 | |
| EP11704673.0A EP2526090B1 (en) | 2010-01-18 | 2011-01-17 | New anti-malarial agents |
| PCT/IB2011/050192 WO2011086531A2 (en) | 2010-01-18 | 2011-01-17 | New anti-malarial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151143T1 true HRP20151143T1 (hr) | 2015-12-04 |
Family
ID=43759659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151143TT HRP20151143T1 (hr) | 2010-01-18 | 2011-01-17 | Novi antimalarijski agensi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9024033B2 (enExample) |
| EP (1) | EP2526090B1 (enExample) |
| JP (1) | JP5735986B2 (enExample) |
| CN (1) | CN102812006B (enExample) |
| BR (1) | BR112012017713A2 (enExample) |
| CA (1) | CA2787121C (enExample) |
| DK (1) | DK2526090T3 (enExample) |
| ES (1) | ES2551875T3 (enExample) |
| HR (1) | HRP20151143T1 (enExample) |
| HU (1) | HUE027946T2 (enExample) |
| ME (1) | ME02315B (enExample) |
| PL (1) | PL2526090T3 (enExample) |
| PT (1) | PT2526090E (enExample) |
| RS (1) | RS54339B1 (enExample) |
| SI (1) | SI2526090T1 (enExample) |
| SM (1) | SMT201500291B (enExample) |
| WO (1) | WO2011086531A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ593969A (en) | 2008-12-19 | 2013-11-29 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
| SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| AU2011253021A1 (en) * | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| MX2013009953A (es) * | 2011-03-04 | 2013-09-26 | Lexicon Pharmaceuticals Inc | Inhibidores de cinasa de mst1 y metodos de su uso. |
| WO2013049859A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| MX353461B (es) | 2011-09-30 | 2018-01-15 | Vertex Pharma | PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR). |
| BR112014020212B1 (pt) | 2012-02-17 | 2021-11-23 | University Of Cape Town | Aminopirazina, formulação farmacêutica, método para prevenir ou tratar malária em um paciente, processo para a preparação de um derivado de aminopirazina, e, intermediário |
| PT2833973T (pt) | 2012-04-05 | 2017-12-21 | Vertex Pharma | Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| MY184855A (en) | 2013-03-15 | 2021-04-27 | Dow Agrosciences Llc | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides |
| US9006250B2 (en) * | 2013-03-15 | 2015-04-14 | Dow Agrosciences Llc | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US10112926B2 (en) * | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| CN107531683B (zh) * | 2015-03-20 | 2022-05-13 | 豪夫迈·罗氏有限公司 | Usp7抑制剂化合物及使用方法 |
| EP3118198A1 (en) | 2015-07-13 | 2017-01-18 | MMV Medicines for Malaria Venture | Anti-malarial agents |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| WO2017067881A1 (en) * | 2015-10-19 | 2017-04-27 | Glaxosmithkline Intellectual Property Development Limited | Pyrazine compounds for use in the treatment of parasitic protozoal infections |
| GB201603104D0 (en) * | 2016-02-23 | 2016-04-06 | Ucb Biopharma Sprl | Therapeutic agents |
| EP3254679A1 (de) | 2016-06-09 | 2017-12-13 | Christian-Albrechts-Universität zu Kiel | Wirkstoffe gegen protozoen und bakterien |
| US11919902B2 (en) * | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| EP3842100A1 (en) * | 2019-12-24 | 2021-06-30 | The Board Of Regents Of The University Of Texas System | Anti-malarial agents |
| CA3264304A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | FURO-PYRIMIDINE DERIVATIVES |
| WO2024033280A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria |
| EP4574143A1 (en) | 2023-12-21 | 2025-06-25 | Universität Regensburg | Inhibitors of plasmodia remodeling enzymes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100574350B1 (ko) | 2004-08-31 | 2006-04-27 | 한국화학연구원 | 2-아미노피리딘 유도체의 제조방법 |
| JP2009507824A (ja) * | 2005-09-12 | 2009-02-26 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 抗マラリアベイリス−ヒルマン付加物およびその調製方法 |
| EP1900727A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| CN101555248B (zh) | 2009-05-22 | 2011-06-22 | 北京欧凯纳斯科技有限公司 | 一种多取代1,5-萘啶化合物的制备方法 |
-
2011
- 2011-01-17 HR HRP20151143TT patent/HRP20151143T1/hr unknown
- 2011-01-17 ES ES11704673.0T patent/ES2551875T3/es active Active
- 2011-01-17 PT PT117046730T patent/PT2526090E/pt unknown
- 2011-01-17 JP JP2012548527A patent/JP5735986B2/ja not_active Expired - Fee Related
- 2011-01-17 EP EP11704673.0A patent/EP2526090B1/en active Active
- 2011-01-17 CN CN201180005928.3A patent/CN102812006B/zh not_active Expired - Fee Related
- 2011-01-17 PL PL11704673T patent/PL2526090T3/pl unknown
- 2011-01-17 CA CA2787121A patent/CA2787121C/en active Active
- 2011-01-17 DK DK11704673.0T patent/DK2526090T3/en active
- 2011-01-17 HU HUE11704673A patent/HUE027946T2/en unknown
- 2011-01-17 WO PCT/IB2011/050192 patent/WO2011086531A2/en not_active Ceased
- 2011-01-17 RS RS20150696A patent/RS54339B1/sr unknown
- 2011-01-17 US US13/522,775 patent/US9024033B2/en active Active
- 2011-01-17 SI SI201130636T patent/SI2526090T1/sl unknown
- 2011-01-17 ME MEP-2015-178A patent/ME02315B/me unknown
- 2011-01-17 BR BR112012017713-3A patent/BR112012017713A2/pt not_active IP Right Cessation
-
2015
- 2015-11-26 SM SM201500291T patent/SMT201500291B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013517264A (ja) | 2013-05-16 |
| SMT201500291B (it) | 2016-01-08 |
| HK1175472A1 (zh) | 2013-07-05 |
| CA2787121A1 (en) | 2011-07-21 |
| ME02315B (me) | 2016-06-20 |
| ES2551875T3 (es) | 2015-11-24 |
| WO2011086531A2 (en) | 2011-07-21 |
| RS54339B1 (sr) | 2016-02-29 |
| PL2526090T3 (pl) | 2016-04-29 |
| EP2526090B1 (en) | 2015-08-19 |
| HUE027946T2 (en) | 2016-11-28 |
| JP5735986B2 (ja) | 2015-06-17 |
| US9024033B2 (en) | 2015-05-05 |
| CA2787121C (en) | 2018-07-17 |
| CN102812006A (zh) | 2012-12-05 |
| WO2011086531A3 (en) | 2011-09-29 |
| CN102812006B (zh) | 2016-01-20 |
| US20120295905A1 (en) | 2012-11-22 |
| SI2526090T1 (sl) | 2015-11-30 |
| EP2526090A2 (en) | 2012-11-28 |
| DK2526090T3 (en) | 2015-10-19 |
| PT2526090E (pt) | 2015-11-30 |
| BR112012017713A2 (pt) | 2020-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151143T1 (hr) | Novi antimalarijski agensi | |
| JP2013517264A5 (enExample) | ||
| US8889718B2 (en) | Thiazole derivatives | |
| JP2005526814A5 (enExample) | ||
| JP2010513444A5 (enExample) | ||
| RU2013102401A (ru) | Анеллированные производные пиридина | |
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| JP2016522246A5 (enExample) | ||
| RU2006136881A (ru) | Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv | |
| AR082458A1 (es) | Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 | |
| HRP20151435T1 (hr) | Diamino heterociklički karboksamidni spoj | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2015143430A (ru) | Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств | |
| JP2004534755A5 (enExample) | ||
| HRP20120748T1 (hr) | Heterocikliäśki spoj i farmaceutski sastavi koji ga sadrže | |
| RU2012132527A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ, ИХ СОДЕРЖАЩАЯ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K | |
| HRP20150347T1 (hr) | Analozi 2-aminopiridina kao aktivatori glukokinaze | |
| HRP20110520T1 (hr) | Acilaminopirazoli kao inhibitori fgfr | |
| JP2008524246A5 (enExample) | ||
| RU2015128025A (ru) | Ингибиторы сомт | |
| RU2012157404A (ru) | Анелированные пиридины в качестве модуляторов рецепторов 5-ht2a и d3 | |
| CA2510519A1 (en) | Condensed furan compounds | |
| JP2007505083A5 (enExample) | ||
| JP2016501883A5 (enExample) | ||
| JP2008526721A5 (enExample) |